- Aratana Therapeutics (NASDAQ:PETX) states a field effectiveness study for its capromorelin (AT-002) drug, which aims to stimulate appetite in dogs, demonstrated "statistically significant increases in appetite compared to placebo (p<0.05)."
- Chief development officer Ernst Heinen: "The results from the pivotal field study demonstrate that capromorelin clearly stimulated appetite in client-owned dogs. We believe it could be a first-in-class approved drug for treating inappetence in dogs."
- Aratana will submit the study data to the FDA's Center for Veterinary Medicine. Based on current FDA approval process timelines, the company "anticipates commencing commercialization of capromorelin for treatment of inappetence in dogs in 2016."
- Shares have jumped to $16.00 AH.